Acrotech Biopharma
NJ - East Windsor
PharmaceuticalFocus: Specialty Pharmaceuticals
Acrotech Biopharma is a life sciences company focused on Specialty Pharmaceuticals.
Neurology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (4)
3 discontinued products not shown
ADQUEY
adquey
Launch
TOPICAL · OINTMENT
phosphodiesterase-4 (PDE-4). Difamilast's inhibition of PDE-4 (a major cyclic adenosine monophosphate (AMP)-metabolizing enzyme) activity leads to accumulation of intracellular cyclic AMP and decreased productions of various cytokines and chemokines. However, the specific mechanism(s) by which difamilast exerts its therapeutic action is not well defined.
atopic dermatitis
2026
18
BELEODAQ
belinostat
LOE Approaching
SMINTRAVENOUS · POWDER
Histone Deacetylase Inhibitors
refractory peripheral T-cell lymphoma (PTCL)lymphoma
2014
15
EVOMELA
melphalan
Peak
INTRAVENOUS · POWDER
type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.
myeloma
2016
0
FOLOTYN
pralatrexate
LOE Approaching
INTRAVENOUS · SOLUTION
reductase. It is also a competitive inhibitor for polyglutamylation by the enzyme folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules the synthesis of which depends on single carbon transfer.
refractory peripheral T-cell lymphoma (PTCL)
2009
30
Pipeline & Clinical Trials
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
Peripheral T-cell LymphomaClinical Trials (1)
NCT01110733Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry
N/ABelinostat
Advanced CancerClinical Trials (1)
NCT01583777Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Phase 1Phase 1
Clinical Trials (1)
NCT02679131To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.
Phase 1Belinostat IV
Solid TumorsClinical Trials (1)
NCT02680795Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
Phase 1Belinostat
Metastatic AdenocarcinomaPralatrexate Injection
Advanced Solid TumorsClinical Trials (1)
NCT07036133Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Phase 1Vincristine Sulfate Liposomes Injection
Malignant MelanomaClinical Trials (1)
NCT00145041Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
Phase 1Talazoparib
Metastatic Breast CancerFusilev
Non Hodgkin's LymphomaClinical Trials (1)
NCT01789723Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Phase 1Ribociclib
Metastatic Breast CancerPralatrexate Injection
Cutaneous T-cell LymphomaClinical Trials (1)
NCT01134341Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1Vitamin B12
Cutaneous T-cell LymphomaClinical Trials (1)
NCT00554827Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Phase 1Pralatrexate Injection
Peripheral T-Cell Lymphoma (PTCL)Clinical Trials (1)
NCT02594267A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Phase 1Vincristine Sulfate Liposome
Hematologic DiseasesClinical Trials (1)
NCT04243434PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
Phase 1Belinostat
Solid TumorClinical Trials (1)
NCT04184869Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Phase 1Folotyn
Non-Small Cell Lung CancerClinical Trials (1)
NCT01820091Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Phase 1Marqibo
SarcomaClinical Trials (1)
NCT01222780To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer
Phase 1Belinostat
Peripheral T-cell LymphomaClinical Trials (1)
NCT01839097Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1Vincristine Sulfate Liposome Injection plus rituximab
Non-Hodgkin's LymphomaClinical Trials (1)
NCT01851551Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL
Phase 1/2Vincristine Sulfate Liposomes Injection
Acute Lymphoblastic LeukemiaClinical Trials (1)
NCT00144963Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 1/2Pralatrexate Injection
Relapsed or Refractory Lymphoproliferative MalignanciesClinical Trials (1)
NCT00481871Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Phase 1/2Belinostat, Carboplatin, Paclitaxel
Stage IV Non-small Cell Lung CancerClinical Trials (1)
NCT01310244MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Phase 1/2High-Dose Melphalan HCL for Injection
Multiple MyelomaClinical Trials (1)
NCT01660633Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Phase 2Pralatrexate Injection
Carcinoma, Transitional CellClinical Trials (1)
NCT00722553Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Phase 2Folotyn and Leucovorin
Relapsed Peripheral T-Cell LymphomaClinical Trials (1)
NCT02106650Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies
Phase 2Melphalan HCL for Injection
Multiple MyelomaClinical Trials (1)
NCT00925782PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Phase 2Pralatrexate Injection
Peripheral T-cell LymphomaClinical Trials (1)
NCT00364923Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Phase 2Blinatumomab
B-cell Acute Lymphoblastic LeukemiaBinimetinib
Metastatic Uveal MelanomaPralatrexate Injection
Breast CancerClinical Trials (1)
NCT01118624Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Phase 2Difamilast
Atopic DermatitisClinical Trials (1)
NCT05571943A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
Phase 3Belinostat Injection
Peripheral T Cell LymphomaClinical Trials (1)
NCT06072131To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Phase 3Difamilast
Atopic DermatitisClinical Trials (1)
NCT05608343This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 7 approved products, 28 clinical trials
Top TAs: Oncology, Immunology
Portfolio Health
Launch1 (14%)
Peak3 (43%)
LOE Approaching3 (43%)
7 total products